

World Cancer Summit 2018

July 02-03, 2018 Bangkok, Thailand

Clinical characteristics, demography and outcome trends of adjuvant anthracycline- and taxane based chemotherapy regimen in early-stage breast cancer- A single centre experience of 264 patients

Ashok K Vaid

Background: Anthracycline- and Taxane based chemotherapy regimen remains the gold standard for the adjuvant chemotherapy treatment of early-stage breast cancer. However, the knowledge on the use and effectiveness of this treatment regimen in real-world setting is limited. This study examined the treatment trends of adjuvant anthracycline- and taxane based chemotherapy regimen in the routine clinical practice at a single tertiary care cancer centre in India.

Methods: Patients with histologically or cytologically confirmed early breast cancer who underwent primary breast surgery followed by adjuvant treatment with anthracycline- and taxane based chemotherapy regimen at Medanta Cancer Institute between 2010 and 2015 were included in the study. Data on clinical characteristics and treatment details was collected from the patient's medical records. Invasive Disease Free Survival (IDFS) was taken as the primary efficacy endpoint.

Results: